Cargando…
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments. Here, we report a microfluidics-based, patient-specific ‘GBM-on-a-Chip’ microphysiological sys...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556869/ https://www.ncbi.nlm.nih.gov/pubmed/32909947 http://dx.doi.org/10.7554/eLife.52253 |
_version_ | 1783594301498851328 |
---|---|
author | Cui, Xin Ma, Chao Vasudevaraja, Varshini Serrano, Jonathan Tong, Jie Peng, Yansong Delorenzo, Michael Shen, Guomiao Frenster, Joshua Morales, Renee-Tyler Tan Qian, Weiyi Tsirigos, Aristotelis Chi, Andrew S Jain, Rajan Kurz, Sylvia C Sulman, Erik P Placantonakis, Dimitris G Snuderl, Matija Chen, Weiqiang |
author_facet | Cui, Xin Ma, Chao Vasudevaraja, Varshini Serrano, Jonathan Tong, Jie Peng, Yansong Delorenzo, Michael Shen, Guomiao Frenster, Joshua Morales, Renee-Tyler Tan Qian, Weiyi Tsirigos, Aristotelis Chi, Andrew S Jain, Rajan Kurz, Sylvia C Sulman, Erik P Placantonakis, Dimitris G Snuderl, Matija Chen, Weiqiang |
author_sort | Cui, Xin |
collection | PubMed |
description | Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments. Here, we report a microfluidics-based, patient-specific ‘GBM-on-a-Chip’ microphysiological system to dissect the heterogeneity of immunosuppressive tumor microenvironments and optimize anti-PD-1 immunotherapy for different GBM subtypes. Our clinical and experimental analyses demonstrated that molecularly distinct GBM subtypes have distinct epigenetic and immune signatures that may lead to different immunosuppressive mechanisms. The real-time analysis in GBM-on-a-Chip showed that mesenchymal GBM niche attracted low number of allogeneic CD154+CD8+ T-cells but abundant CD163+ tumor-associated macrophages (TAMs), and expressed elevated PD-1/PD-L1 immune checkpoints and TGF-β1, IL-10, and CSF-1 cytokines compared to proneural GBM. To enhance PD-1 inhibitor nivolumab efficacy, we co-administered a CSF-1R inhibitor BLZ945 to ablate CD163+ M2-TAMs and strengthened CD154+CD8+ T-cell functionality and GBM apoptosis on-chip. Our ex vivo patient-specific GBM-on-a-Chip provides an avenue for a personalized screening of immunotherapies for GBM patients. |
format | Online Article Text |
id | pubmed-7556869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-75568692020-10-16 Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy Cui, Xin Ma, Chao Vasudevaraja, Varshini Serrano, Jonathan Tong, Jie Peng, Yansong Delorenzo, Michael Shen, Guomiao Frenster, Joshua Morales, Renee-Tyler Tan Qian, Weiyi Tsirigos, Aristotelis Chi, Andrew S Jain, Rajan Kurz, Sylvia C Sulman, Erik P Placantonakis, Dimitris G Snuderl, Matija Chen, Weiqiang eLife Cancer Biology Programmed cell death protein-1 (PD-1) checkpoint immunotherapy efficacy remains unpredictable in glioblastoma (GBM) patients due to the genetic heterogeneity and immunosuppressive tumor microenvironments. Here, we report a microfluidics-based, patient-specific ‘GBM-on-a-Chip’ microphysiological system to dissect the heterogeneity of immunosuppressive tumor microenvironments and optimize anti-PD-1 immunotherapy for different GBM subtypes. Our clinical and experimental analyses demonstrated that molecularly distinct GBM subtypes have distinct epigenetic and immune signatures that may lead to different immunosuppressive mechanisms. The real-time analysis in GBM-on-a-Chip showed that mesenchymal GBM niche attracted low number of allogeneic CD154+CD8+ T-cells but abundant CD163+ tumor-associated macrophages (TAMs), and expressed elevated PD-1/PD-L1 immune checkpoints and TGF-β1, IL-10, and CSF-1 cytokines compared to proneural GBM. To enhance PD-1 inhibitor nivolumab efficacy, we co-administered a CSF-1R inhibitor BLZ945 to ablate CD163+ M2-TAMs and strengthened CD154+CD8+ T-cell functionality and GBM apoptosis on-chip. Our ex vivo patient-specific GBM-on-a-Chip provides an avenue for a personalized screening of immunotherapies for GBM patients. eLife Sciences Publications, Ltd 2020-09-10 /pmc/articles/PMC7556869/ /pubmed/32909947 http://dx.doi.org/10.7554/eLife.52253 Text en © 2020, Cui et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Cui, Xin Ma, Chao Vasudevaraja, Varshini Serrano, Jonathan Tong, Jie Peng, Yansong Delorenzo, Michael Shen, Guomiao Frenster, Joshua Morales, Renee-Tyler Tan Qian, Weiyi Tsirigos, Aristotelis Chi, Andrew S Jain, Rajan Kurz, Sylvia C Sulman, Erik P Placantonakis, Dimitris G Snuderl, Matija Chen, Weiqiang Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title_full | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title_fullStr | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title_full_unstemmed | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title_short | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy |
title_sort | dissecting the immunosuppressive tumor microenvironments in glioblastoma-on-a-chip for optimized pd-1 immunotherapy |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556869/ https://www.ncbi.nlm.nih.gov/pubmed/32909947 http://dx.doi.org/10.7554/eLife.52253 |
work_keys_str_mv | AT cuixin dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT machao dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT vasudevarajavarshini dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT serranojonathan dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT tongjie dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT pengyansong dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT delorenzomichael dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT shenguomiao dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT frensterjoshua dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT moralesreneetylertan dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT qianweiyi dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT tsirigosaristotelis dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT chiandrews dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT jainrajan dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT kurzsylviac dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT sulmanerikp dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT placantonakisdimitrisg dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT snuderlmatija dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy AT chenweiqiang dissectingtheimmunosuppressivetumormicroenvironmentsinglioblastomaonachipforoptimizedpd1immunotherapy |